Last year was a good one for medtech companies.
Large companies saw their share prices grow, with Covidien's share price growing the most. Even as the Irish company bid goodbye to the markets as a standalone company prior to the consummation of the deal with Medtronic, it saw its share price grow the most—53%—out of large-cap medtech companies. In fact, shares of all large caps grew in 2014, according to a report by EP Vantage, the publishing arm of market intelligence firm Evaluate.
The company that performed the worst out of the large-cap companies was St. Jude Medical, whose stock inched up a mere 5%.
But among medtech companies whose market capitalization is less than $15 billion, which were the big market movers, both up and down. Here is a slideshow that provides the answers based on EP Vantage data.